EMEA VOLUME 9A PDF

This guidance shall be published in Volume 9 of The rules .. ANNEX I – VEDDRA list of Clinical Terms (EMEA/CVMP/ /Final). in consultation with the European Medicines Agency (EMEA – “the Agency”) Structure of Volume 9A Part I deals with Guidelines for. Flag of European Union portal · Other countries · Atlas · v · t · e. EudraLex is the collection of rules and regulations governing medicinal products in the European Union. Contents. 1 Volumes; 2 Directives; 3 See also; 4 References; 5 External links. Volumes[edit]. EudraLex consists of 10 volumes: Volume 9 – Pharmacovigilance.

Author: Taura Douktilar
Country: Burkina Faso
Language: English (Spanish)
Genre: Art
Published (Last): 11 July 2016
Pages: 141
PDF File Size: 6.42 Mb
ePub File Size: 1.80 Mb
ISBN: 201-4-75524-166-2
Downloads: 70243
Price: Free* [*Free Regsitration Required]
Uploader: Faugami

The pharmaceutical company should maintain a system, normally a validated database, for ensuring that any adverse drug reactions reported to the pharmaceutical company can be recorded, classified and, wmea necessary, retrieved worldwide. Therefore, routine audits are advisable. National law allows the authorities to impose sanctions if the results are unsatisfactory.

In view of the complexity of the requirements and the resulting manpower requirements, businesses with a smaller number of marketing authorisations are at a disadvantage compared volumf their larger competitors when it comes to PV; the more marketing authorisations a company manages, the more experience it acquires, thus enhancing the quality and efficiency of its pharmacovigilance procedures.

The Marketing Authorisation Holder is responsible for the safety of its products and must undertake to commission a Qualified Person for Pharmacovigilance QPPV to monitor the safety of medicinal products and to voolume this person with the requisite resources to do so.

Eudralex – Pharmacovigilance for Medical Products Volume 9a

In this regard, outsourcing also represents an effective and consistent response by the pharmaceutical industry to the continuous pressure exterted by international regulations on safety issues. At the same time, there are synergy effects in terms of cost structures.

These points must also be defined in the SOP. Service providers may handle spontaneous reports instead of the Vloume Authorisation Holder. Volume 9A outlines certain requirements on the basis of which inspections are conducted. Records must be kept of the initial and further training of the personnel who are assigned PV activities. The purpose of the Detailed Description of the Pharmacovigilance System DDPS which is formalised 9q Volume 9A is to describe the actual safety-monitoring practice followed in the company.

  GRACELING KRISTIN CASHORE EPUB PDF

Training courses Records must volumw kept of the initial and further training of the personnel who are assigned PV activities.

Quality Management System A brief description of the quality management system should also be submitted. This, for example, may take the form of co-marketing contracts which include a contractual provision on reporting spontaneous incidents.

Pursuant to Volume 9A, e. There should also be a diagram organisation chart depicting the structure of the organisation in order to illustrate the general outline within the company and in relation to external partners.

The QPPV must, for instance, maintain an overview of safety profiles and precautions for the medicinal products or implement them in the first instance.

There should also be a cross-reference to a training SOP, which is used as a basis for training all the employees in question on how to emeq spontaneous reports. Product-specific additions, such as the exchange of safety-related data with a licensing partner, should be illustrated in an appendix. Cookies helfen uns bei der Bereitstellung unserer Dienste. If there are errors in the DDPS or if it is not submitted at all, volum approval application will be rejected for formal reasons.

Where relevant, the Marketing Authorisation Holder must vplume a detailed description of the following components of its PV system cf. The external contracting partner must implement quality assurance and quality controls. If, for example, the receipt of spontaneous reports is contracted out to a call centre, the Marketing Authorisation Holder has to ensure that the personnel concerned receive training volumr perform audits to ensure that the call centre agents are trained in how to receive and pass on spontaneous reports.

The possible disadvantages identified in outsourcing are a potential dependence on external third parties or upon the reliability of their work. Anja op de Bekke Dr. Furthermore, the inspectors shall examine individual elements, such as the recording, processing and quality of incident reports, the data-acquisition system or the job descriptions of employees who are involved in the creation of PV documents.

In any event, the costs of an inspection shall be borne by the pharmaceutical company.

In short, the QPPV is responsible for ensuring that the PV system in the company conforms to current statutory regulations and is vlume in full. EudraLex Volume 9A requires Marketing Authorisation Holders to invest considerable manpower and financial resources in monitoring the safety of pharmaceutical products.

Designing Efficient Pharmacovigilance Systems

Whether the decisive factor is having an opportunity to participate in PSUR compilation service projects for known active ingredients or whether keeping the workload in check is what matters, Marketing Authorisation Holders frequently contract out the preparation of PSURs to specialised service providers.

  HTC DESIRE C HANDLEIDING NEDERLANDS PDF

Close This website uses cookies We use cookies to improve the user experience. Qualified Person Responsible for Pharmacovigilance The Marketing Authorisation Holder is responsible for the safety of its products and must undertake to commission a Qualified Person for Pharmacovigilance QPPV to monitor the safety of medicinal products and to provide this person with the requisite resources to do so. It is important to remember, for example, that even where medicinal products are only approved nationally for example in Germany, suspected serious and unexpected adverse drug reactions experienced in non-EU member states still have to be reported electronically to the EMEA’s EudraVigilance database by specially trained personnel.

Documentation The PV system, of course, also includes storage of the compiled documents. Special attention should be given to the quality assurance of the PV system, as well as to auditing external service providers.

Guidelines Regulations – GMP Navigator

Therefore, pharmaceutical companies producing low-risk medicinal products are turning increasingly to specialised PV service providers. In addition to the structure of the database and data back-up, attention must also be paid to standards for reporting adverse drug reactions, EudraVigilance registration, updating and validation. Contractual Arrangements The points to be disclosed in the DDPS also include contractual agreements with people or businesses relating to pharmacovigilance.

The pharmaceutical company will be given an opportunity to demonstrate its PV system during any inspection, which generally takes one or few day s.

Designing Efficient Pharmacovigilance Systems

This practice is permitted explicitly in Volume 9A part 1, point 1. Supporting documentation can be added to the DDPS, confirming that the PV system is in correct working order and, if relevant, providing volums about changes or revisions to the system.

External service providers and consultants may be involved in virtually any pharmacovigilance process.

ICSRs represent an interesting yet sensitive area in the cooperation between pharmaceutical companies and external service providers.